IMR Press / RCM / Special Issues / 1626054694825


Submission deadline: 15 March 2022
Special Issue Editors
  • Yen-Wen Wu
    Division of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan
    Interests: Atherosclerosis; Heart failure; Cardio-oncology; Cardiomyopathy; Nuclear cardiology; Biomarker; Functional imaging
  • Hung-Ju Lin
    Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei,Taiwan
    Interests: Cardiovascular epidemiology; Hypertension; Cardio-oncology
  • Yen-Wen Liu
    Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University
    Interests: Stem cell research; Cardiac regeneration; Echocardiography; Cancer therapy related cardiac dysfunction; Cardio-oncology
  • Pei-Wei Shueng
    Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan
    Interests: Stereotactic Body Radiation Therapy (SBRT); Image-Guided Radiotherapy (IGRT); Radiation related cardiotoxicity; Radiation related pneumonitis
Special Issue Information

Dear Colleagues,


The two top causes of death in the world are cancer and cardiovascular disease, and cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. Cancer treatment has advanced rapidly from surgery, cytotoxic chemotherapy, radiation therapy, and targeted and immune-based therapies over the past decades. These advances have led to an increase in the number of cancer survivors, however an emerging issue associated with these new cancer therapies is side effects on the cardiovascular system, which cause different spectrums of morbidity and mortality. In order to explor and detect cancer therapeutics–related cardiovascular dysfunction and mitigate its progression, the both fields are closely intertwined with each other.  

This Special Issue takes specific focus on the current state of cardio-oncology field and especially cancer therapy-related cardiac dysfunction—exploring the mechnisms, reviewing the current status including dignoastic and imaging modalites, team-based care and personalised approaches, and clinical unmet needs, with recommendations to minimise the risk of cardiovascular toxicity from cancer therapies and the development of dedicated cardio-oncology care.

Dr. Yen-Wen Wu, Dr. Hung-Ju Lin, Dr. Yen-Wen Liu and Dr. Pei-Wei Shueng

Guest Editors

Cancer therapy-related cardiac dysfunction
Heart failure
Diagnostic and prognostic application
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (3 Papers)
Back to top